SMO and B-cell chronic lymphocytic leukemia: Decker and Ghia observed that in CLL samples, Hh signaling activation was associated with early disease progression and increased sensitivity to Gli1 inhibition, which seems to be more effective when compared to SMO inhibitors in overcoming stroma-mediated protective effects [49,50].